These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Perilymphatic injections of cytokines: a new tool in active cancer immunotherapy. Experimental rationale and clinical findings. Forni G; Giovarelli M; Jemma C; Bosco MC; Caretto P; Modesti A; Santoni A; Forni M; Cortesina G; de Stefani A Ann Ist Super Sanita; 1990; 26(3-4):397-409. PubMed ID: 2151108 [TBL] [Abstract][Full Text] [Related]
3. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors. Nitta K; Tanaka T; Takeuchi M Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657 [TBL] [Abstract][Full Text] [Related]
7. Human transitional cell carcinoma in the NMRI-nu/nu mouse bladder: a new animal model for the in vivo use of monoclonal antibodies and cytotoxic agents. Huland E; Arndt R; Huland H Cancer Res; 1986 May; 46(5):2488-9. PubMed ID: 3697989 [TBL] [Abstract][Full Text] [Related]
8. Influence of misonidazole on the radiosensitivity of transplantable transitional cell bladder carcinoma in mice. Hampel N; Persky L Invest Urol; 1981 Jul; 19(1):14-6. PubMed ID: 7251317 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343 [TBL] [Abstract][Full Text] [Related]
10. [Experimental study on an active specific immunotherapy modified with irradiation. 1. Effect of the immunotherapy combined with radiotherapy]. Ogawa Y; Takashima H; Imanaka K; Okuno T; Hiratsuka J; Ichiyanagi A; Ashida C; Oshitani T; Imajo Y; Kimura S Nihon Gan Chiryo Gakkai Shi; 1982 Apr; 17(3):752-7. PubMed ID: 6813404 [No Abstract] [Full Text] [Related]
11. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480 [TBL] [Abstract][Full Text] [Related]
12. Effect of corynebacterium liquefaciens on a C3Hf mouse squamous cell carcinoma. Ando K; Urano M; Nesumi N; Koike S Cancer Res; 1977 Sep; 37(9):3115-9. PubMed ID: 884666 [TBL] [Abstract][Full Text] [Related]
13. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor. Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207 [TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer. Yu DS; Lee CF; Hsieh DS; Chang SY Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475 [TBL] [Abstract][Full Text] [Related]
15. Local control and disease-free survival after treatment of a squamous cell carcinoma by Corynebacterium parvum and local irradiation. Suit HD; Sedlacek R; Silobrcic V Cancer Res; 1977 Nov; 37(11):3869-75. PubMed ID: 908026 [No Abstract] [Full Text] [Related]
16. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model. Hegele A; Dalpke A; Barth P; Varga Z; Heeg K; Hofmann R; Olbert P Anticancer Res; 2004; 24(4):2225-30. PubMed ID: 15330165 [TBL] [Abstract][Full Text] [Related]
17. In vitro evidence for increased cellular immunity to lung cancer antigen during Levamisole immunotherapy. Urist MM; Boddie AW; Townsend CM; Holmes EC J Thorac Cardiovasc Surg; 1977 Feb; 73(2):189-94. PubMed ID: 834057 [TBL] [Abstract][Full Text] [Related]
18. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer. Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine. Lee CF; Chang SY; Hsieh DS; Yu DS J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345 [TBL] [Abstract][Full Text] [Related]
20. [An attempt to control the growth of syngeneic experimental tumors in inbred mice using Listeria factor Ei, BCG vaccine and a combination of both]. Zák M; Mára M; Jirkovský J Sb Lek; 1989 Sep; 91(8):230-7. PubMed ID: 2617123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]